USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Stratatech Corporation
Address:
505 S. Rosa Road, Suite 169
Madison, WI
EIN:
392025242
DUNS:
160392168
Number of Employees:
28
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,616,084.00 18
SBIR Phase II $19,184,643.00 12
STTR Phase I $353,615.00 3
STTR Phase II $3,171,837.00 3

Award List:

Development of a Human Intraepithelial Cancer Model

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,350.00
Agency:
HHS
Principal Investigator:
Paul B. Conrad
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Over half of all human cancers occur in squamous epithelia. In order to enhance drug discovery for the treatment of squamous cell carcinoma (SCC) and other cancers, it is essential to have an organotypic in vitro model which… More

BARRIER FUNCTION IN NORMAL IMMORTALIZED KERATINOCYTE

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Allen R. Comer
Abstract:
DESCRIPTION: (Verbatim) - The goal of this proposal is to optimize the barrier function properties of a human skin equivalent culture for eventual commercialization as an in vitro test for chemicals and formulations. Human skin equivalent assays are the best… More

Reporter gene assays for skin irritation assessment

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,435.00
Agency:
HHS
Principal Investigator:
Allen R. Comer
Abstract:
DESCRIPTION (Applicant's Abstract): The goal of this proposal is to establish reporter gene assays that utilize human skin equivalent cultures for testing the irritancy potential of chemical compounds. The assays will utilize a new and proprietary human skin cell line called… More

Cryopreservation of a Living Human Skin Equivalent

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$101,350.00
Agency:
HHS
Principal Investigator:
Paul B. Conrad
Abstract:
DESCRIPTION (provided by applicant): Production of a living human skin equivalent (LSE) that is economical, mechanically durable and provides effective barrier function for the treatment of epithelial trauma (e.g., burns and diabetic lesions) is a highly prized goal… More

EXPRESSION OF ANGIOGENIC GROWTH FACTORS IN KERATINOCYTES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of these studies is to provide a genetically-improved cultered skin substitute product for use in the treatment of burns and chronic wounds. The current products include wild-type keratinocytes or fibroblasts in collagen-based or artificial matrixes. Genetic analysis of the wound healing… More

Expression of Angiogenic Growth Factors in Keratinocytes

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$774,329.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent advances in tissue engineering hold great promise for alleviating the current shortage of tissues and organs available for transplantation. However, engineered skin tissue produced with primary human keratinocytes is slow to vascularize following… More

Engineering a Human Organ for Dry Storage

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$99,802.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Tissue engineering is a field with tremendous untapped potential, current revenues ($232 million in 2000, Genetic Engineering News 9/15/01) fall far short of the estimated market of $100 billion (Barron's, 5/15/00). This gap is in large part due to the… More

Antimicrobial, Angiogenic Skin Substitutes for Diabetic*

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$1,094,388.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this application is to develop a genetically engineered therapeutic human skin substitute with enhanced antimicrobial and angiogenenic properties for use in the treatment of type 1 diabetic skin ulcers. Chronic diabetic skin ulcers exhibit poor… More

Clinical Evaluation of StrataGraft Skin Tissue

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe burns and other major trauma to the skin are life-threatening injuries that often require immediate surgical intervention. Typically, this involves temporary coverage of the wound site with cadaver skin or synthetic dressings to prevent infection and… More

Development of a Cell-Derived Human Skin Substitute for Acute and Chronic Wounds

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$1,484,347.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Severe burns and other major trauma to the skin are life-threatening injuries that often require immediate surgical intervention. Typically, this involves temporary coverage of the wound site with cadaver skin or synthetic dressings to prevent infection and… More

Development of Innovative Human Stromal Invasion Assay

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$99,975.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF WISCONSIN
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this STTR proposal is to develop an innovative human tumor invasion assay for use as a screening tool in the identification of new anti-tumor therapeutics. Development of a model of early stage tumor invasion, the precursor condition to… More

Enhancing the Vascularization Properties of Skin Tissue

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$167,958.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cutaneous ulcers afflict approximately 4.5 million patients in the United States each year and it is estimated that 15% of older adults in the United States suffer from chronic, hard-to-heal skin wounds. Many of these wounds fail to heal, often resulting in… More

Clinical Trial of Antimicrobial Skin to treat Diabetic Ulcers

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$2,334,559.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this application is to develop a genetically engineered therapeutic human skin substitute with enhanced antimicrobial and angiogenenic properties for use in the treatment of type 1 diabetic skin ulcers. Chronic diabetic skin ulcers exhibit poor… More

Closed, Aseptic Production Process for Engineered Living Human Skin Tissue

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$196,099.00
Agency:
HHS
Principal Investigator:
Allen R. Comer
Abstract:
DESCRIPTION (provided by applicant): Tissue engineering (TE) is poised to make an enormous impact on the range of therapeutic options for treatment of life-threatening conditions that afflict millions of Americans. To date, however, no marketed TE product has proven to be commercially successful.… More

Closed, Aseptic Production Process for Engineered Living Human Skin Tissue

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$779,049.00
Agency:
HHS
Principal Investigator:
Allen R. Comer
Abstract:
DESCRIPTION (provided by applicant): Tissue engineering (TE) is poised to make an enormous impact on the range of therapeutic options for treatment of life-threatening conditions that afflict millions of Americans. To date, however, no marketed TE product has proven to be commercially successful.… More

Enhancing the Vascularization Properties of Skin Tissue

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,585,339.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): To date no biological treatment options specifically targeting the hypoxic nature of chronic wounds have been developed and marketed. While administration of individual angiogenic factors may stimulate some aspects of a ngiogenesis, the simultaneous expression of… More

Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of Vesicant Burns

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$69,630.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Barry Steiglitz, Molecular Biology Scientist
Abstract:
Cutaneous wounds, such as those resulting from vesicant exposure and thermal injuries, provide an ideal environment for bacterial growth and the complications stemming from wound sepsis. The availability of ready-to-use, antimicrobial skin substitutes that are readily deployed in the field would… More

Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of Vesicant Burns

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$749,790.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Barry Steiglitz, Molecular Biology Scienti
Abstract:
Cutaneous wounds, such as those resulting from vesicant exposure and thermal injuries, provide an ideal environment for bacterial growth and the complications stemming from wound sepsis. The availability of ready-to-use, antimicrobial skin substitutes that are readily deployed in the field would… More

Cell-Based, Chronic Wound Gene Therapy for Older Adults

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$1,186,084.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): To date no biological treatment options specifically targeting the proteolytic nature of chronic wounds have been developed and marketed. Chronic skin wounds constitute an important medical problem for the growing age d population. 18% of diabetic patients over… More

Tissue-Based Cytokine Immunotherapy for Skin Cancer

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$210,395.00
Agency:
HHS
Principal Investigator:
Mary A. Lokuta
Abstract:
DESCRIPTION (provided by applicant): The National Cancer Institute projects that more than 1,000,000 cases of skin cancer will be diagnosed in the United States in 2008, including more than 62,000 new cases of melanoma. Although surgical excision of the pr imary tumor is curative for the majority of… More

Tissue-Based Cytokine Immunotherapy for Skin Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$937,440.00
Agency:
HHS
Principal Investigator:
Mary A. Lokuta
Abstract:
DESCRIPTION (provided by applicant): The National Cancer Institute projects that more than 1,000,000 cases of skin cancer will be diagnosed in the United States in 2008, including more than 62,000 new cases of melanoma. Although surgical excision of the pr imary tumor is curative for the majority of… More

Natural Polymers for Cranio-facial Tissue Engineering

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$99,983.00
Agency / Branch:
DOD / OSD
Principal Investigator:
Mary A. Lokuta, Preclinical Research Scientist
Abstract:
Complex craniofacial tissue loss is a major medical problem affecting deployed military personnel. During the ongoing conflicts in Iraq and Afghanistan, approximately 88% of injured troops sustain severe blast-related injuries to their head and neck from improvised explosive devices. These severe… More

Development of a Cell-Derived Human Skin Substitute for Acute and Chronic Wounds

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,499,661.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Burns and trauma to the skin affect an estimated 1.25 million Americans each year. Extensive damage to the skin has serious repercussions, leading to dehydration, increased metabolic load, entry of toxic substances, immunosuppression, and wound infection.… More

Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Chronic and infected wounds significantly affect the quality of life for millions of US citizens and are associated with increased risk of complications including the devastating consequence of amputation. As of 2006, i nfections of diabetic foot ulcers resulted… More

An Innovative Full-Thickness Human Skin Model for Increased Throughput Screening in Drug Discovery

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$149,383.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a full-thickness in vitro human skin model in a format enabling increased-throughput screening of compounds. The project will 1) develop culture conditions for production of fibroblast-derived dermal equivalents, 2)… More

A Human Intraepithelial Tumor Microenvironment Assay

Award Year / Program / Phase:
2010 / STTR / Phase II
Award Amount:
$1,164,582.00
Agency:
HHS
Principal Investigator:
Barbara L. Allen-hoffmann – 608-441-2756
Research Institution:
University Of Wisconsin System
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The goal of this STTR project is to develop innovative human tumor microenvironment (TM) assays for use as screening tools in the identification of new anti-tumor therapeutics. Novel assay technologies are needed for the discovery of new drugs, and combinations… More

SBIR Phase II: An Innovative Full-Thickness Human Skin Model for Increased Throughput Screening in Drug Discovery

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$499,877.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project proposes to develop a high-throughput assay incorporating 3-D skin models capable of accurately identifying and characterizing DNA damage. There is an urgent need for improved genotoxicity assays for safety screening in drug… More

Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Allen R. Comer – 608-441-2759
Abstract:
DESCRIPTION (provided by applicant): Chronic and infected wounds significantly affect the quality of life for millions of US citizens and are associated with increased risk of complications including the devastating consequence of amputation. As of 2006, infections of diabetic foot ulcers resulted… More

A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$4,540,318.00
Agency:
HHS
Principal Investigator:
Mary A. Lokuta – 608-441-8358
Abstract:
DESCRIPTION (provided by applicant): The goal of this Type 2 Competitive Renewal SBIR application to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct a phase I/II clinical trial to investigate the safety and earlyefficacy of a novel antimicrobial living… More

TAS::75 0862::TAS 3D SKIN MODEL W/ENHANCED SENSIVITY and THROUGHPUT

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$178,327.00
Agency:
HHS
Principal Investigator:
Kathy Ramussen – 608-441-2756
Abstract:
In vitro skin models have shown excellent potential for the evaluation of acute skin irritation. However, the current systems lack the ability to discriminate between mild and strong irritants and require labor-intensive protocols that limit test throughput. To address the three critical limitations… More

Chimeric Autologous/Allogeneic Constructs for Skin Regeneration

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$149,989.00
Agency:
DOD
Principal Investigator:
Cathy Rasmussen, Senior Scientist – (608) 441-2748
Abstract:
Complex skin defects, including burns and trauma, represent a major medical problem affecting both military and civilian populations. In recent military engagements, burns account for approximately 5% of combat casualties. Furthermore, approximately 1.25 million Americans each year require medical… More

StrataScreenSENS, Skin Sensitizer Detection in Luminescent 3D Human Skin Models

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$199,995.00
Agency:
HHS
Principal Investigator:
Cathy Rasmussen – 608-441-2756
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop an innovative in vitro assay for the classification of skin sensitizers that permits evaluation of chemicals within the highly relevant context of a three-dimensional model of human skin that more closely mimics the… More

Chimeric Autologous/Allogeneic Constructs for Skin Regeneration

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$999,934.00
Agency:
DOD
Principal Investigator:
Cathy Rasmussen, Senior Scientist – (608) 441-2748
Abstract:
Complex skin defects, including burns and trauma, represent a major medical problem affecting both military and civilian populations. In recent military engagements, burns account for approximately 5% of combat casualties. Furthermore, approximately 1.25 million Americans each year require medical… More